GEODE CAPITAL MANAGEMENT, LLC - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 69 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$91,969
-15.7%
117,9090.0%0.00%
Q2 2023$109,065
-5.5%
117,909
+11.3%
0.00%
Q1 2023$115,441
+74861.7%
105,9100.0%0.00%
Q4 2022$154
-99.8%
105,910
+45.5%
0.00%
Q3 2022$78,000
-36.6%
72,7690.0%0.00%
Q2 2022$123,000
-17.4%
72,7690.0%0.00%
Q1 2022$149,000
-45.2%
72,7690.0%0.00%
Q4 2021$272,000
-27.7%
72,7690.0%0.00%
Q3 2021$376,000
+21.7%
72,7690.0%0.00%
Q2 2021$309,000
-19.9%
72,7690.0%0.00%
Q1 2021$386,000
+45.7%
72,769
+47.9%
0.00%
Q4 2020$265,000
-70.0%
49,188
-55.5%
0.00%
Q3 2020$883,000
+44.8%
110,655
+81.5%
0.00%
Q2 2020$610,000
+338.8%
60,952
+18.6%
0.00%
Q1 2020$139,000
-40.6%
51,389
-73.8%
0.00%
Q4 2019$234,000
+143.8%
196,014
+206.3%
0.00%
Q3 2019$96,000
-62.6%
64,0000.0%0.00%
Q2 2019$257,000
-6.5%
64,0000.0%0.00%
Q1 2019$275,000
-38.9%
64,000
-18.5%
0.00%
Q4 2018$450,000
-16.2%
78,496
+97.9%
0.00%
Q3 2018$537,000
+10.3%
39,655
-3.6%
0.00%
Q2 2018$487,000
+0.4%
41,137
-4.8%
0.00%
Q1 2018$485,000
+153.9%
43,211
+50.7%
0.00%
Q4 2017$191,000
-18.4%
28,667
+0.2%
0.00%
Q3 2017$234,000
+82.8%
28,6050.0%0.00%
Q2 2017$128,000
+39.1%
28,605
+69.9%
0.00%
Q1 2017$92,000
+39.4%
16,841
+2.6%
0.00%
Q4 2016$66,000
-41.6%
16,421
+1.7%
0.00%
Q3 2016$113,000
+36.1%
16,141
+57.1%
0.00%
Q2 2016$83,00010,2730.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q1 2019
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$1,501,2502.44%
NEA Management Company, LLC 17,079,779$18,616,9581.29%
Endurant Capital Management LP 1,660,835$1,810,3100.93%
Matrix Capital Management Company, LP 38,974,185$42,481,8620.58%
Long Focus Capital Management, LLC 5,435,439$5,924,6290.34%
PFM Health Sciences, LP 5,992,571$6,531,9020.29%
Key Client Fiduciary Advisors, LLC 321,155$350,0590.22%
DAFNA Capital Management LLC 351,064$382,6600.12%
Rock Springs Capital Management LP 2,787,845$3,038,7510.07%
Baker Brothers Advisors 9,830,877$10,715,6560.06%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders